MX2024005024A - Terapia combinada para tratar crecimiento celular anormal. - Google Patents
Terapia combinada para tratar crecimiento celular anormal.Info
- Publication number
- MX2024005024A MX2024005024A MX2024005024A MX2024005024A MX2024005024A MX 2024005024 A MX2024005024 A MX 2024005024A MX 2024005024 A MX2024005024 A MX 2024005024A MX 2024005024 A MX2024005024 A MX 2024005024A MX 2024005024 A MX2024005024 A MX 2024005024A
- Authority
- MX
- Mexico
- Prior art keywords
- cell growth
- abnormal cell
- treating abnormal
- combination therapy
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163272899P | 2021-10-28 | 2021-10-28 | |
| PCT/US2022/078771 WO2023076991A1 (en) | 2021-10-28 | 2022-10-27 | Combination therapy for treating abnormal cell growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005024A true MX2024005024A (es) | 2024-05-13 |
Family
ID=86158717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005024A MX2024005024A (es) | 2021-10-28 | 2022-10-27 | Terapia combinada para tratar crecimiento celular anormal. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250009746A1 (https=) |
| EP (1) | EP4422617A4 (https=) |
| JP (1) | JP2024540015A (https=) |
| KR (1) | KR20240095266A (https=) |
| CN (1) | CN118510505A (https=) |
| AU (1) | AU2022376939A1 (https=) |
| CA (1) | CA3235499A1 (https=) |
| IL (1) | IL312248A (https=) |
| MX (1) | MX2024005024A (https=) |
| WO (1) | WO2023076991A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021206684B2 (en) | 2020-01-10 | 2024-01-18 | Immuneering Corporation | MEK inhibitors and therapeutic uses thereof |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| WO2024054591A1 (en) * | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| TW202517624A (zh) * | 2023-07-03 | 2025-05-01 | 美商醫療免疫工程公司 | Mek免疫腫瘤抑制劑醫藥組合物 |
| CN116570599B (zh) * | 2023-07-04 | 2023-10-20 | 四川大学华西医院 | Vs6766联合ly3009120的应用及药物组合物 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10668055B2 (en) * | 2013-12-20 | 2020-06-02 | Biomed Valley Discoveries, Inc. | Cancer treatment using combinations of ERK and RAF inhibitors |
| US20170112865A1 (en) * | 2014-05-21 | 2017-04-27 | The Board Of Regents Of The University Of Texas System | Treatment for melanoma |
| JP6864990B2 (ja) * | 2015-04-16 | 2021-04-28 | 日東電工株式会社 | Ｂｒａｆ遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物 |
| KR20200037820A (ko) * | 2017-08-07 | 2020-04-09 | 에볼 사이언스 엘엘씨 | 암을 치료하기 위한 조합 |
| JP2022547358A (ja) * | 2019-09-13 | 2022-11-14 | ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル | 治療組成物、組み合わせ、及び使用方法 |
-
2022
- 2022-10-27 EP EP22888488.8A patent/EP4422617A4/en active Pending
- 2022-10-27 CA CA3235499A patent/CA3235499A1/en active Pending
- 2022-10-27 CN CN202280078087.7A patent/CN118510505A/zh active Pending
- 2022-10-27 MX MX2024005024A patent/MX2024005024A/es unknown
- 2022-10-27 KR KR1020247017024A patent/KR20240095266A/ko active Pending
- 2022-10-27 US US18/702,569 patent/US20250009746A1/en active Pending
- 2022-10-27 IL IL312248A patent/IL312248A/en unknown
- 2022-10-27 WO PCT/US2022/078771 patent/WO2023076991A1/en not_active Ceased
- 2022-10-27 JP JP2024525058A patent/JP2024540015A/ja active Pending
- 2022-10-27 AU AU2022376939A patent/AU2022376939A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022376939A1 (en) | 2024-05-02 |
| JP2024540015A (ja) | 2024-10-31 |
| CN118510505A (zh) | 2024-08-16 |
| CA3235499A1 (en) | 2023-05-04 |
| EP4422617A4 (en) | 2025-10-15 |
| KR20240095266A (ko) | 2024-06-25 |
| EP4422617A1 (en) | 2024-09-04 |
| IL312248A (en) | 2024-06-01 |
| US20250009746A1 (en) | 2025-01-09 |
| WO2023076991A1 (en) | 2023-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005024A (es) | Terapia combinada para tratar crecimiento celular anormal. | |
| CO2020015255A2 (es) | Métodos y composiciones para tratar el cáncer | |
| BR112022004699A2 (pt) | Vs-6063 em combinação com ch5126766 para o tratamento de câncer | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| BR112023000675A2 (pt) | Terapia de combinação para tratamento de crescimento celular anormal | |
| MX2024002838A (es) | Metodos para tratar trastornos usando inhibidores de csf1r. | |
| MX2024001248A (es) | Terapia de combinacion para tratar el crecimiento celular anormal. | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| MX2022009347A (es) | Terapia de combinacion para el tratamiento del crecimiento celular anormal. | |
| CO2024009571A2 (es) | Inhibidores de parp1 | |
| BR112023021913A2 (pt) | Tratamento de câncer com inibidor de raf | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| MX2019006622A (es) | Composicion farmaceutica para la prevencion o tratamiento de cancer, que comprende polimorfo cristalino de hexoxido de tetraarsenico. | |
| BR112018077136A2 (pt) | composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis. | |
| BR112023015616A2 (pt) | Terapia de combinação para tratamento de crescimento celular anormal | |
| MX2019005737A (es) | Composicion farmaceutica para prevenir o tratar el cancer de cerebro que incluye polimorfocristalino de hexaoxido de tetraarsenico y metodo para preparar el mismo. | |
| UY33476A (es) | Estimuladores de sgc | |
| MX2017010598A (es) | Hoja de acero laminada en caliente. | |
| EA201991622A1 (ru) | Комплексная терапия для лечения рака | |
| BR112016021034A8 (pt) | composição farmacêutica, uso da mesma e kit | |
| CO2021002691A2 (es) | Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1) | |
| MX2018003301A (es) | Inhibidores de pcna. | |
| PH12020551995A1 (en) | Modulator of apol1 expression | |
| WO2023108110A3 (en) | Combination therapy for treating abnormal cell growth | |
| MX2022007626A (es) | Combinaciones. |